Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using a micro-organism to make a protein or polypeptide
Reexamination Certificate
2008-04-08
2008-04-08
Kam, Chih-Min (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using a micro-organism to make a protein or polypeptide
C435S252700, C435S253600, C424S811000, C424S236100, C424S239100
Reexamination Certificate
active
07354740
ABSTRACT:
Chromatographic processes and systems for purifying abotulinumtoxin from an APF fermentation medium.
REFERENCES:
patent: 6558926 (2003-05-01), Demain et al.
patent: 2003/0008367 (2003-01-01), Oguma
patent: 2003/0118598 (2003-06-01), Hunt
patent: WO 94/09115 (1993-10-01), None
patent: WO 96/05222 (1995-06-01), None
patent: WO 98/54296 (1998-05-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01-36655 (2000-10-01), None
patent: WO 01/58472 (2001-02-01), None
Coligan, et al.,Current protocols in protein science, Front Matter, Aug. 2003.
Lungdahl, L.G., et al., Working with anaerobic bacteria,Manual of Industrial Microbiology and Biotechnology, Chp. 8, 1986, pp. 84-96.
Mueller, J.H., et al., Variable factors influencing the product of tetanus toxin,J. Bacteriol, 1954; 67:271-7.
Ozutsumi, K., et al., Rapid, simplified method for production and purification of tetanus toxin,Applied and Environmental Microbiology, Apr. 1985, vol. 49, No. 4, pp. 939-943.
Chp. 1, pp. 1-88, Strategies of Protein Purification and Characterization,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed, Chp. 21, pp. 1-282.
Chp. 21, pp. 1-282, Peptidases,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed.
Heenan, C. N., et al., Lehensm.-Wiss. U.-Technol, 35 (2002), pp. 171-176.
Miwa, Norinaga, et al., International Journal of Food Microbiology, 49 (1999), pp. 103-106.
Mueller, J. H., et al., J. Bacteriology, Mar. 1954, 67(3), pp. 271-277.
Whitmer, M. E., et al., Applid and Environmental Microbiology, Mar. 1988, 54(3), pp. 753-759.
Oxoid—Product CM0149—product description, pp. 1-2, 2004.
Bedu-Addo, F., et al.,Use of Biophysical Characterization in Preformulation Developmnt of a Heavy-Chain Fragment of Botulinum Serotype B: Evaluation of Suitable Purificaiton Process Conditions, Pharmaceutical Research, Aug. 2004, vol. 21, No. 8, pp. 1353-1361.
Byrne, M., et al.,Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia Pastoris as a Recombinant Vaccine Candidate, Infection and Immunity, Oct. 1998, vol. 66, No. 10, pp. 4817-4822.
Byrne, M., et al.,Fermentation, Purification, and Efficacy of a Recombinant Vaccine Candidate Against Botulinum Neurotoxin Type F from Pichia pastoris, Protein Expression and Purification, 2000, 18, pp. 327-337.
Gessler, F., et al.,Production and Purification of Clostridium Botulinum Type C and D Neurotoxin, FEMS Immunology and Medical Microbiology, 1999, vol. 24, pp. 361-367.
Gimenez, J., et al.,Simplified Purification Method for Clostridium Botulinum Type E Toxin, Applied and Environmental Microbiology, Dec. 1987, vol. 53, No. 12, pp. 2827-2830.
Johnson, S., et al.,Scale-up of the Fermentation and Purification of the Recombinant Havy Chain Fragment C of Botulinum Neurotoxin Serotype F, Expressed in Pichia Pastoris, Protein Expression and Purification, 2003, vol. 32, pp. 1-9.
Kozaki, H., et al.,Immunological Characterization of Papain-Induced Fragments of Clostridium Botulinum Type A Neurotoxin and Interaction of the Fragments with Brain Synaptosomes, Infection and Immunity, 1989, vol. 57,. No. 9, pp. 2634-2639.
Prabakaran, S., et al.,Botulinum Neurotoxin Types B and E: Purification, Limited Proteolysis by Endoproteinase Glu-C and Pepsin, and Comparison of Their Identified Cleaved Sites Relative to the Three-Dimensional Structure of Type A Neurotoxin, Toxicon, 2001, vol. 39, pp. 1515-1531.
Weatherly, G., et al.,Initial Purification of Recombinant Botulinum Neurotoxin Fragments for Pharmaceutical Production Using Hydrophobic Charge Induction of Chromatography, Journal of Chromatography A, 2002, vol. 952, pp. 99-110.
Bonventre, P.F., et al., Physiology of toxin production by clostridium botulinum types A and B,College of Medicine, vol. 7, pp. 372-374, 1959.
Chen, F., et al., Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component and the 900-kilodalton botulinum toxin complex species,Infect ImmunJun. 1998;66(6):2420-2425.
Holderman, L., et al., A study of the nutritional requirements and toxin production of clostridium botulinum type F,Canadian Journal of Microbiology, vol. 11, (1965), pp. 1009-1019.
Johnson, E., et al., Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective,Toxicon 39(2001) 1703-1722.
Karasawa, T., et al., A defined growth medium for clostridium difficle,Microbiology(1995), 141, 371-375.
Kohl, A., et al., Comparison of the effect of botulinum toxin A (BOTOX®) with the highly-purified neurotoxin (NT201) n the extensor digitorum brevis muscle test,MOV DISORD, 2000;15(Suppl 3):165.
Lewis, K.H., et al., Practical media and control measures for highly toxic cultures of clostridium botulinum type A,Production of Botulinum Toxin, pp. 213-230, 1947.
Li, Y., et al., Expression and characterization of the heavy chain of tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form,J Biochem(Tokyo) Jun. 1999;125(6):1200-1208.
Naumann, M., et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,Euro. J. Neurology1999:6(Suppl 4):S111-S115.
Porfirio, Z., et al., Specific peptides of casein pancreatic digestion enhance the production of tetanus toxin,J. of Applied Microbiology, 1997 83:678-684.
Ragona, Rosario Marchese, et al., Management of Parotid Sialocele with botulinum toxin,The Laryngoscope, 109:Aug. 1999:pp. 1344-1346.
Siegel, L.S., Fermentaton kinetics of botulinum toxin production (types A, B and E),Biomedical aspects of botulism, New York: Academic Press 1981:pp. 121-128.
Schantz, E.J., et al., Preparation and characterization of botulinum toxin type A for human treatment, Jankovic J, ed.;Neurological Disease and Therapy. Therapy withBotulinum Toxin, 1994;25:pp. 41-49.
Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial neurotoxins in medicine,Microbiological Reviews, Mar. 1992, p. 80-99.
Schiefer-Ullrich, H., et al., Comparative studies on physiology and taxonomy of obligatory purinolytic clostridia,Arch Microbiol, 1984, 138:345-353.
Whitmer, M.E., et al., Development of improved defined media for clostridium botulinum serotypes A, B and E,Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, p. 753-759.
Siegel, L.S., et al.,Toxin Production by Clostridium botulinum Type A Under Various Fermentation Conditions, Applied and Envirmonmental Microbiology, Oct. 1979, pp. 606-611.
Huhtanen, C.N.,Some Observations on a Perigo-Type Inhibition of Clostridium botulinum in a Simplified Medium, J. Milk Food Technol., Dec. 1975, vol. 38, No. 12, pp. 761-763.
Schantz, E.J., et al.,Use of Crystalline Type A Botulinum Toxin in Medical Research, Biomedical Aspects of Botulism, Academic Press, Inc., edited by George E. Lewis, Jr. 1981, pp. 143-150.
Whitmer, Mary E., et al.,Development of Improved Defined Media for Clostridium botulinum Serotypes A, B, and E, Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, pp. 753-759.
Donovan Stephen
Luo Mingjiang
Wang Ping
Xiang Hui
Allergan Inc.
Donovan Stephen
Kam Chih-Min
LandOfFree
Animal product free system and process for purifying a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Animal product free system and process for purifying a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Animal product free system and process for purifying a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2754828